The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1

The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1

Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer. T-DM1 consists of trastuzumab covalently linked to the cytotoxic maytansinoid DM1 via a non-cleavable linker. Despite its efficacy,...

Full description

Bibliographic Details
Main Authors: Mercedes Nadal-Serrano, Beatriz Morancho, Santiago Escrivá-de-Romaní, Cristina Bernadó Morales, Antonio Luque, Marta Escorihuela, Martín Espinosa Bravo, Vicente Peg, Fred A. Dijcks, Wim H.A. Dokter, Javier Cortés, Cristina Saura, Joaquín Arribas
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
breast cancer
her2
antibody-drug conjugate
syd985
t-dm1
patient-derived xenograft
Online Access:https://www.mdpi.com/2072-6694/12/3/670

Internet

https://www.mdpi.com/2072-6694/12/3/670

Similar Items